BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Little Benefit From Pfizer Inc. (PFE) & Bristol-Myers Squibb Company (BMY) Bloodthinner


3/16/2012 7:45:15 AM

Pfizer Inc. (PFE) and Bristol-Myers Squibb Co. (BMY)’s Eliquis offered little to no added benefit for patients who had undergone elective hip or knee replacement surgery when compared to Sanofi’s Lovenox, a German health agency said today. The Institute for Quality and Efficiency in Health Care, otherwise known as IQWiG, said the newer medicine offered no added benefit for prevention of venous thromboembolic events in knee surgery patients. Eliquis, known chemically as apixaban, offered a low additional benefit for hip surgery patients, the agency said in a statement posted on its website today.

Read at BusinessWeek

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES